Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 76.60
Change Today +2.00 / 2.68%
Volume 740.8K
BLRX On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
Tel Aviv
As of 10:24 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd (BLRX) Snapshot

Open
$77.50
Previous Close
$74.60
Day High
$77.50
Day Low
$76.20
52 Week High
03/4/15 - $105.90
52 Week Low
12/3/14 - $46.80
Market Cap
409.7M
Average Volume 10 Days
622.6K
EPS TTM
$-0.13
Shares Outstanding
534.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD (BLRX)

biolinerx ltd (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. It also has four therapeutic candidates in the preclinical stages of development, including BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies and asthma; BL-9020 for the treatment of type 1 diabetes; and BL-1110 for the treatment of neuropathic pain and scleroderma. The company has strategic collaboration with Novartis Pharma AG for the co-development of drug candidates. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

46 Employees
Last Reported Date: 03/23/15
Founded in 2003

biolinerx ltd (BLRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $366.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $269.0K
Vice President of Business Development
Total Annual Compensation: $241.0K
Vice President of Medical Affairs
Total Annual Compensation: $185.0K
Chief Scientific Officer
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

biolinerx ltd (BLRX) Key Developments

BioLineRx, Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioLineRx, Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015.  For the quarter, the company reported operating loss of USD 4,327,000 against USD 4,076,000 a year ago. Net loss was USD 4,311,000 or USD 0.008 per basic and diluted share against USD 2,115,000 or USD 0.010 per diluted share a year ago. Net cash used in operating activities was USD 3,468,000 against USD 3,391,000 a year ago. Purchase of property and equipment was USD 149,000 against USD 47,000 a year ago. The USD 0.1 million increase in net cash used in operating activities during the three-month period in 2015, compared to the three-month period in 2014, was primarily the result of increased research and development spending, partially offset by an increase in trade payables and accruals.

BioLineRx, Ltd. to Report Q1, 2015 Results on May 18, 2015

BioLineRx, Ltd. announced that they will report Q1, 2015 results at 9:00 AM, Israel Standard Time on May 18, 2015

BioLineRx, Ltd., Q1 2015 Earnings Call, May 18, 2015

BioLineRx, Ltd., Q1 2015 Earnings Call, May 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:IT 76.60 +2.00

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.